Tenofovir Alafenamide Fumarate Tablets (Meiganneng) – 25?mg × 30 Tablets

Tenofovir Alafenamide Fumarate Tablets (Meiganneng) – 25?mg × 30 Tablets

$2.00

Meiganneng Tenofovir Alafenamide Fumarate (TAF) tablets provide 25?mg per tablet, 30 tablets per bottle. Manufactured by Hunan Mingrui Pharmaceutical Co., Ltd., approved under H20213856. TAF is a liver-targeting nucleotide analog prodrug used in preclinical research for hepatitis B and HIV models, offering improved safety vs. older tenofovir forms.
?? For laboratory and research use only. Not for clinical applications.?Please consult staff for other specifications and uses?

EMI starting from $0.00/month - View Plans
Compare

Description

TAF is a potent nucleotide reverse transcriptase inhibitor delivering active tenofovir into hepatocytes and lymphocytes with minimal renal exposure, improving safety compared to Tenofovir Disoproxil Fumarate (TDF) . The fumarate salt enhances stability and tablet formulation performance .
Meiganneng tablets are formulated for research into antiviral efficacy, resistance development, metabolic processing, and comparative safety studies in HBV and HIV infection models.


Product Specifications

ParameterDetails
Product NameTenofovir Alafenamide Fumarate Tablets (Meiganneng)
Generic NameTenofovir Alafenamide Fumarate (TAF)
CAS Number1392275?56?7
Molecular FormulaC??H??N?O?P·C?H?O?
Molecular Weight??1069?Da
Strength25?mg per tablet
Pack Size30 tablets per bottle
Dosage FormOral tablet
Approval NumberH20213856 (NMPA China)
ManufacturerHunan Mingrui Pharmaceutical Co., Ltd.
Barcode6920945600377
Storage ConditionsStore ??25?°C, protected from moisture
Intended UseLaboratory research: HBV & HIV antiviral studies, pharmacokinetics

Mechanism of Action

TAF is a prodrug converted intracellularly to tenofovir diphosphate, which blocks viral reverse transcriptase, inhibiting viral replication. It has enhanced hepatic targeting and a better safety profile (lower renal/bone toxicity) versus TDF.


Research Applications

  • HBV antiviral efficacy and resistance assays

  • HIV preclinical replication and combination therapy research

  • Comparative pharmacokinetics vs. TDF

  • Toxicology: bone and kidney safety in vitro/in vivo

  • Mechanistic studies of nucleotide analog activation and metabolism


Safety & Handling

  • For research purpose only—no clinical or veterinary use

  • Use with standard lab PPE (gloves, coat, goggles)

  • Store sealed, in a dry, cool environment (??25?°C)

  • Dispose per institutional regulations


Core Keywords

tenofovir alafenamide fumarate, TAF 25?mg tablets, CAS 1392275?56?7, Meiganneng TAF, antiviral research compound, HBV HIV nucleotide RT inhibitor, laboratory tenofovir alafenamide


Research Use Disclaimer

This product is strictly for laboratory and preclinical research use. It is not approved for clinical, diagnostic, therapeutic, or veterinary applications. Improper use may result in health or regulatory consequences. Use only under appropriate protocols.

Additional information

Weight1 kg
Dimensions23 × 26 × 23 cm

Reviews

There are no reviews yet.

Be the first to review “Tenofovir Alafenamide Fumarate Tablets (Meiganneng) – 25?mg × 30 Tablets”

Your email address will not be published. Required fields are marked *

EMI Options

Select at least 2 products
to compare